Lantheus Holdings, Inc. LNTH
We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals ("HCPs") Find, Fight and Follow cancer. Our Precision Diagnostic products assist HCPs to Find and Follow diseases. Our Strategic Partnerships include biomarkers and digital solutions in support of our partners' therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically, and contract development and manufacturing organization ("CDMO") revenue generated by Evergreen.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.54B | $1.53B | $1.30B | $935.1M | $425.2M | $339.4M | $347.3M | $343.4M | $331.4M | $301.9M |
| Cost of revenue | $599.7M | $545.6M | $586.9M | $353.4M | $237.5M | $200.6M | $172.5M | $168.5M | $169.2M | $164.1M |
| Gross profit | $942.0M | $988.3M | $709.5M | $581.7M | $187.7M | $138.8M | $174.8M | $174.9M | $162.1M | $137.8M |
| R&D | $177.3M | $168.1M | $77.7M | $311.7M | $45.0M | $32.8M | $20.0M | $17.1M | $18.1M | $12.2M |
| SG&A | $275.1M | $193.7M | $125.5M | $133.6M | $150.4M | $69.3M | $61.2M | $50.2M | $49.8M | $38.8M |
| Total operating expenses | — | — | — | — | — | $143.0M | $123.2M | $110.4M | $110.3M | — |
| Operating income | $310.8M | $457.0M | $364.6M | $36.2M | -$60.8M | -$4.2M | $51.7M | $64.5M | $51.9M | $56.6M |
| Interest expense | $19.7M | $19.7M | $20.0M | $7.2M | $7.8M | $9.5M | $13.6M | $17.4M | $18.4M | $26.6M |
| Pre-tax income | $313.8M | $431.0M | $410.9M | $26.7M | -$75.0M | -$11.5M | $28.6M | $49.5M | $39.6M | $28.3M |
| Income tax | $80.2M | $118.5M | $84.3M | $1.3M | $3.8M | $2.0M | $3.0M | $9.0M | $83.7M | $1.5M |
| Net income | $233.6M | $312.4M | $326.7M | $28.1M | -$71.3M | -$13.5M | $31.7M | $40.5M | $123.4M | — |
| EPS, basic | 3.46 | 4.52 | 4.79 | 0.41 | -1.06 | -0.25 | 0.81 | 1.06 | 3.31 | 0.84 |
| EPS, diluted | 3.41 | 4.36 | 4.65 | 0.40 | -1.06 | -0.25 | 0.79 | 1.03 | 3.17 | 0.82 |
| Shares, diluted (wtd. avg.) | $68.4M | $71.7M | $70.2M | $70.7M | $67.5M | $54.1M | $40.1M | $39.5M | $38.9M | $32.7M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $359.1M | $912.8M | $713.7M | $417.2M | $100.7M | $82.7M | $92.9M | $113.4M | $76.3M | $51.2M |
| Receivables | $358.6M | $321.3M | $284.3M | $213.4M | $89.3M | $54.0M | $43.5M | $43.8M | $40.3M | $36.8M |
| Inventory | $64.7M | $68.0M | $64.0M | $35.5M | $35.1M | $35.7M | $29.2M | $33.0M | $26.1M | $17.6M |
| Total current assets | $900.0M | $1.33B | $1.09B | $677.6M | $235.8M | $184.2M | $172.9M | $195.4M | $147.8M | $110.8M |
| Property, plant and equipment | $163.7M | $176.8M | $146.7M | $122.2M | $116.8M | $120.2M | $116.5M | $107.9M | $93.0M | $94.2M |
| Goodwill | $239.5M | $61.2M | $61.2M | $61.2M | $61.2M | $58.6M | $15.7M | $15.7M | $15.7M | $15.7M |
| Other intangibles | $722.8M | $161.8M | $152.0M | $315.3M | $348.5M | $376.0M | $7.3M | $9.1M | $11.8M | $15.1M |
| Total assets | $2.23B | $1.98B | $1.65B | $1.32B | $863.8M | $869.8M | $405.9M | $439.8M | $383.9M | $255.9M |
| Accounts payable | $42.9M | $34.6M | $41.2M | $20.6M | $20.8M | $16.3M | $18.6M | $18.0M | $17.5M | $18.9M |
| Short-term debt | $738.0K | $974.0K | $823.0K | $354.0K | $11.6M | $20.7M | $10.1M | $2.8M | $2.8M | $3.6M |
| Total current liabilities | $333.4M | $240.5M | $187.3M | $247.7M | $90.5M | $80.5M | $66.1M | $52.8M | $46.8M | $43.8M |
| Long-term debt | — | — | — | $557.7M | $163.1M | $197.7M | $183.9M | $263.7M | $265.4M | $274.5M |
| Total liabilities | $1.14B | $892.3M | $835.3M | $874.1M | $399.3M | $355.6M | $291.3M | $368.8M | $360.6M | $362.4M |
| Retained earnings | $679.5M | $445.9M | $133.5M | -$193.2M | -$221.2M | -$149.9M | -$136.5M | -$168.1M | -$209.0M | -$332.4M |
| Total equity | $1.09B | $1.09B | $815.9M | $447.1M | $464.4M | $514.2M | $114.6M | $71.0M | $23.3M | -$106.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $390.1M | $544.8M | $305.3M | $281.8M | $53.9M | $16.4M | $80.4M | $61.2M | $54.8M | $49.6M |
| Depreciation and amortisation | $70.1M | $64.6M | $60.0M | $47.9M | $42.3M | $24.7M | $13.4M | $13.9M | $19.2M | $18.3M |
| Stock-based compensation | $85.6M | $76.4M | $50.5M | $29.3M | $15.9M | $14.1M | $12.5M | $8.7M | $5.9M | $2.5M |
| Capital expenditure | $36.1M | $51.6M | $46.6M | $18.3M | $0 | $0 | $22.1M | $20.1M | $17.5M | $7.4M |
| Investing cash flow | -$627.2M | -$226.0M | $5.9M | -$276.5M | $3.7M | -$4.9M | -$22.1M | -$19.1M | -$16.3M | $3.3M |
| Financing cash flow | -$316.6M | -$118.5M | -$13.1M | $311.7M | -$39.3M | -$21.9M | -$78.9M | -$4.7M | -$13.4M | -$30.2M |
| Buybacks | $300.0M | $100.0M | $0 | $75.0M | $0 | $0 | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-073498.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $42.18B | 40.9x | 10.4% |
| CLDX | Celldex Therapeutics, Inc. | $3.12B | — | -78.0% |
| NEOG | NEOGEN CORP | $2.58B | — | -2.7% |
| NTLA | Intellia Therapeutics, Inc. | $1.79B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $958.0M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $873.6M | — | — |
| TKNO | Alpha Teknova, Inc. | $371.5M | — | 7.4% |
| MYGN | MYRIAD GENETICS INC | $305.1M | — | -1.6% |